Stapokibart Shows Safety and Efficacy in Children with Atopic Dermatitis (EMJ Reviews) - Nov 29, 2025 - "Overall, stapokibart was well tolerated. Mild or moderate adverse events occurred in 68% of participants, with no severe treatment-related reactions and no new safety signals. Importantly, no anti-drug antibodies were detected during the study, suggesting low immunogenicity...By week 8, more than half (53.8%) of children in the higher-weight group and three-quarters (75.0%) in the lower-weight group achieved EASI-75, a benchmark indicating at least a 75% improvement in eczema severity."
P1/2 data • Atopic Dermatitis
|